Site Announcement

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Team

Management

Phillip Frost, M.D. Headshot

Phillip Frost, M.D.

Chief Executive Officer and Chairman

Dr. Frost has been CEO and Chairman of OPKO since March 2007. Previously, he served as Chairman and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He has served as Chairman for Key Pharmaceuticals from 1972 until its acquisition by Schering Plough Corporation in 1986 and Ladenburg Thalmann Financial Services from 1977 until its acquisition by Schering Plough in 1986, and was a Director of Castle Brands and Northrop Grumman. He was also a Governor of the American Stock Exchange from 1992 to 2008 and Co-Vice Chairman from 2001 until its merger with the New York Stock Exchange.

Dr. Frost has been a member of the Board of Trustees of the University of Miami since 1983 and was Chairman from 2001 to 2004 e Trustee of the Miami Jewish Home for the Aged and serves on the Executive Committee of the Mount Sinai Medical Center. He also serves e is a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Regents of The Smithsonian Institution from 2006 to 2010.

Dr. Frost is a Director of Cocrystal Pharma, a publicly traded biotechnology company developing new treatments for viral diseases, and Non-Invasive Monitoring Systems, Inc., a public shell company.

Jane Hsiao, Ph.D. Headshot

Jane Hsiao, Ph.D.

Chief Technical Officer and Vice Chairman

Dr. Hsiao has served as Vice Chairman and Chief Technical Officer at OPKO since May 2007 and as a Director since February 2007. Previously, Dr. Hsiao served as Vice Chairman-Technical Affairs of IVAXfrom 1995 to Januarry 2006, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary from 1998 to 2006. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical and Neovasc.

Since 2008 Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, a medical device company, and was named interim CEO of the company in 2012. Dr. Hsiao is also a Director of Asensus Surgical, Inc., a medical device company, and Cocrystal Pharma.

Elias A. Zerhouni, M.D. Headshot

Elias A. Zerhouni, M.D.

President and Vice Chairman

Dr. Zerhouni is Chairman and co-founder of ModeX Therapeutics, OPKO’s wholly-owned subsidiary focused on delivering multispecific therapies for cancer and viral diseases, and has served as President and Vice Chairman of OPKO since May 2022. A physician-scientist in Imaging and Biomedical Engineering, he previously served as President of Global R&D and Executive Vice President of Sanofi from 2010 to 2018, as Senior Fellow for global health research at the Bill & Melinda Gates Foundation and as Presidential U.S. envoy for science and technology from 2009 to 2010. Since 2019, he has also served as a director of B-FLEXION Capital, a private, entrepreneurial investment firm and as Chairman of the Board of Boston Pharmaceuticals, a wholly owned subsidiary of B-FLEXION Capital and a clinical stage biopharmaceutical company, since 2024. He was Director of the U.S. National Institutes of Health from 2002 to 2008, Executive Vice Dean and Dean for Research at the Johns Hopkins School of Medicine, as well as Professor of Radiology and Biomedical Engineering and Chair of the Department of Radiological Sciences from 1996 to 2002.

Dr. Zerhouni was elected to the National Academy of Medicine in 2002 and to the National Academy of Engineering in 2013. He was elected to the governing council of the National Academy of Medicine in 2025. He serves on the Board of the Lasker Foundation, the Foundation for the National Institutes of Health and Research!America. He received the 2017 Scripps Executive of the Year Award for the pharmaceutical industry and the French Legion of Honor in 2008. Since 2009, he has been a Director of Danaher Corporation, a publicly traded a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world.

Giovanni Abbadessa, M.D., Ph.D. Headshot

Giovanni Abbadessa, M.D., Ph.D.

Chief Medical Officer, ModeX

Dr. Abbadessa has been Chief Medical Officer of ModeX. He is an entrepreneurial oncology developer with advanced technical and leadership experience. In his previous post at Sanofi, he rose to become Global Project Head and Vice President, Oncology Early Development, and ushered in numerous oncology therapies at all phases of development including preclinical. He has published over 50 peer-reviewed articles in medical and scientific journals and continues to be active in the oncology community.

In addition, Dr. Abbadessa serves on multiple panels and committees, including those of European Society for Medical Oncology – Targeted Anticancer Therapies. He completed his oncology clinical fellowship in Milan, Italy, and his genetic oncology training at the University of Siena, Italy and the Temple-Fox Chase Cancer Center in Philadelphia.

Hans Berner Headshot

Hans Berner

President, OPKO Health Iberoamerica

Mr. Berner has been with OPKO since 2009 and since April 2018 has served as President of OPKO Health Iberoamerica, which encompasses business units in Brazil, Chile, Mexico, Spain and Uruguay. Mr. Berner has extensive experience in the Latin American pharmaceutical industry, previously overseeing operations in Argentina, Mexico and Uruguay as Corporative General Manager of Laboratorios ELEA S.A. Additionally, he worked as both the Latin American Regional Director for the IVAX Corporation and the General Manager of IVAX Argentina and IVAX Uruguay. He also served as Business Development Manager at Laboratorio Chile S.A. and as Finance Manager at ING Bank Chile.

With over 15 years of teaching experience at various universities, Mr. Berner holds a Professorship at the Pontificia Universidad Católica de Chile, instructing MBA students in the subjects of competitive strategy and M&A.

Mr. Berner earned a commercial engineering degree from the Universidad de Santiago de Chile and an MBA from the Business School of Pontificia Universidad Católica Argentina. He subsequently entered post-graduate studies at Babson College in Entrepreneurship, and holds a master’s in clinical and health psychology from TECH Technological University, Spain.

Charles Bishop, Ph.D. Headshot

Charles Bishop, Ph.D.

Chief Executive Officer, OPKO Renal

Dr. Bishop has served as CEO of OPKO’s Renal Division since its formation following OPKO's acquisition of Cytochroma in March 2013, where he had served as President and CEO since June 2006. Dr. Bishop co-founded Proventiv Therapeutics and served as President while its lead drug, CTAP101 Capsules, was approved by the FDA as Rayaldee® (calcifediol).

Dr. Bishop held various senior management positions at Bone Care International, a public specialty pharmaceutical company focused on vitamin D hormone therapies, including President, CEO, Director, Executive Vice President of Research and Development and Chief Scientific Officer. Under his direction, Bone Care advanced a portfolio of proprietary vitamin D hormones and analogs to varying stages of development for secondary hyperparathyroidism (SHPT), metabolic bone disease, psoriasis and cancers of the prostate, breast and colon. Bone Care was acquired by Genzyme in July 2005.

Dr. Bishop held various management positions in the Health Care Division of Procter & Gamble. He completed a four-year National Institutes of Health postdoctoral fellowship in vitamin D biochemistry at the University of Wisconsin-Madison and received his Ph.D. degree in nutritional biochemistry from Virginia Tech, after earning an undergraduate degree in chemistry from the University of Virginia. Dr. Bishop has published more than 50 scientific papers and is named on more than 60 U.S. patents.

Damien Burke Headshot

Damien Burke

Chief Executive Officer, Eirgen Pharma

Mr. Burke has served as CEO of EirGen Pharma, a company specializing in the development and commercial supply of high potency pharmaceutical products including oncology products. He has over 20 years of experience in the pharmaceutical industry and has held a number of senior leadership positions in supply chain, operations and business development. He holds an MSc. in supply chain and operational management from the University of Liverpool.

Established in 2006, EirGen has grown rapidly and now exports products to over 40 countries worldwide including the EU, U.S., Canada and Japan from its state-of-the-art high containment facility. The facility is licensed by the Irish HPRA, U.S. FDA and Japanese PMDA regulatory authorities.

Adam Logal Headshot

Adam Logal

Senior Vice President and Chief Financial Officer

Mr. Logal has served as OPKO's Senior Vice President and Chief Financial Officer since March 2014, and previously as Vice President of Finance, Chief Accounting Officer and Treasurer, Director of Finance and Chief Accounting Officer since our inception in 2007.

Previously, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. There he held various positions of increasing responsibility, last serving as Senior Director of Accounting and Reporting. Mr. Logal served as Chairman of Xenetics Biosciences, a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics from 2017 until 2024. He also previously served as a Director of VBI Vaccines.

John Mascola, M.D. Headshot

John Mascola, M.D.

Chief Scientific Officer, ModeX

Dr. Mascola joined OPKO’s ModeX Therapeutics as Chief Scientific Officer in 2022. He is an accomplished physician-scientist, virologist and immunologist, and was most recently Director of the Vaccine Research Center (VRC), NIAID, NIH where he oversaw research programs on vaccines and antibody therapeutics, as well as the development of investigational products for major diseases such as HIV, Ebola, respiratory syncytial virus, chikungunya and malaria. Under his leadership, the VRC established collaborative partnerships leading to the licensure of therapeutic antibodies and vaccines for Ebola and COVID-19.

Dr. Mascola earned a medical degree from Georgetown University and completed a residency in internal medicine and a fellowship in infectious diseases. He was a research physician at the Walter Reed Army Institute of Research, where he began his studies on HIV immunology and vaccine development. He joined the VRC as a founding investigator and subsequently served as its Director. Dr. Mascola has received numerous awards and recognitions, including the outstanding service medal from the U.S. Department of Health and Human Services. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians and the National Academy of Medicine.

Gary J. Nabel, M.D., Ph.D. Headshot

Gary J. Nabel, M.D., Ph.D.

Chief Innovation Officer and Director

Dr. Nabel is President and CEO of ModeX Therapeutics, and has served as Chief Innovation Officer and a Director of OPKO since May 2022. He previously worked as Chief Scientific Officer and Senior Vice President of Sanofi until his retirement in 2020e Dr. Nabel graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard, completing his Ph.D. in 1980 and his M.D. two years later, followed by a post-doctoral fellowship with David Baltimore at the Whitehead Institute.

In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, Dr. Nabel was elected to the National Academy of Medicine in 1998 and is a fellow of the American Association of Physicians, and the American Academy of Arts Sciences. Dr. Nabel received the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, the Health and Human Services Secretary’s Award for Distinguished Service. He currently serves on the board of Siga Technologies, a publicly traded a commercial stage pharmaceutical company focused on providing solutions for unmet needs in health security, and Candel Therapeutics, Inc. (NASDAQ: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer.

Steve Rubin Headshot

Steve Rubin

Executive Vice President, Administration and Director

Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a Director since February 2007. 

Mr. Rubin currently serves as a Director of Entera Bio Ltd, a clinical stage company focused on developing oral peptide and protein replacement therapeutics; Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation; Non-Invasive Monitoring Systems, a public shell company; Cocrystal Pharma, a biotechnology company developing new treatments for viral diseases; and Niagen Bioscience, Inc., a global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research; and Red Violet, a leading analytics and information solutions provider. Mr. Rubin previously served as a director of Neovasc, Inc., a company that developed and marketed medical specialty vascular devices

Mr. Rubin previously served as a Director of Castle Brands, Dreams, SafeStitch Medical, Cogent, PROLOR Biotech, BioCardia and VBI Vaccines. 

Gene Yau Headshot

Gene Yau

Head of Business Development

Gene Yau is Head of Business Development where he leads licensing, M&A initiatives and portfolio strategy, to advance the development portfolio and drive enterprise value creation through strategic partnerships and corporate development strategies.

Gene is a seasoned executive who brings over 20 years of experience building and scaling companies through value-defining strategy, partnering, and successful transaction execution. Over his career, he has led transactions totaling over $11 billion in aggregate deal value. Prior to joining OPKO, Gene served as Executive Director and Head of Corporate Development and Strategy at Nimbus Therapeutics, where he led multiple licensing and M&A transactions across its portfolio in immunology, oncology, and metabolic disease. He also held leadership roles at Blueprint Medicines, Astellas, Monsanto, Abbott, and William Blair, building a unique combination of scientific, financial, and strategic expertise across biotechnology and pharmaceuticals.

Gene holds a B.S. in Biochemistry from the University of Illinois Urbana-Champaign, an M.S. in Biotechnology from Northwestern University, and an MBA from the University of Chicago Booth School of Business.

Board of Directors

Phillip Frost, M.D.

Chief Executive Officer and Chairman

Dr. Frost has been CEO and Chairman of OPKO since March 2007. Previously, he served as Chairman and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He has served as Chairman for Key Pharmaceuticals from 1972 until its acquisition by Schering Plough Corporation in 1986 and Ladenburg Thalmann Financial Services from 1977 until its acquisition by Schering Plough in 1986, and was a Director of Castle Brands and Northrop Grumman. He was also a Governor of the American Stock Exchange from 1992 to 2008 and Co-Vice Chairman from 2001 until its merger with the New York Stock Exchange.

Dr. Frost has been a member of the Board of Trustees of the University of Miami since 1983 and was Chairman from 2001 to 2004 e Trustee of the Miami Jewish Home for the Aged and serves on the Executive Committee of the Mount Sinai Medical Center. He also serves e is a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Regents of The Smithsonian Institution from 2006 to 2010.

Dr. Frost is a Director of Cocrystal Pharma, a publicly traded biotechnology company developing new treatments for viral diseases, and Non-Invasive Monitoring Systems, Inc., a public shell company.

Jane Hsiao, Ph.D.

Chief Technical Officer and Vice Chairman

Dr. Hsiao has served as Vice Chairman and Chief Technical Officer at OPKO since May 2007 and as a Director since February 2007. Previously, Dr. Hsiao served as Vice Chairman-Technical Affairs of IVAXfrom 1995 to Januarry 2006, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary from 1998 to 2006. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical and Neovasc.

Since 2008 Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, a medical device company, and was named interim CEO of the company in 2012. Dr. Hsiao is also a Director of Asensus Surgical, Inc., a medical device company, and Cocrystal Pharma.

Elias A. Zerhouni, M.D.

President and Vice Chairman

Dr. Zerhouni is Chairman and co-founder of ModeX Therapeutics, OPKO’s wholly-owned subsidiary focused on delivering multispecific therapies for cancer and viral diseases, and has served as President and Vice Chairman of OPKO since May 2022. A physician-scientist in Imaging and Biomedical Engineering, he previously served as President of Global R&D and Executive Vice President of Sanofi from 2010 to 2018, as Senior Fellow for global health research at the Bill & Melinda Gates Foundation and as Presidential U.S. envoy for science and technology from 2009 to 2010. Since 2019, he has also served as a director of B-FLEXION Capital, a private, entrepreneurial investment firm and as Chairman of the Board of Boston Pharmaceuticals, a wholly owned subsidiary of B-FLEXION Capital and a clinical stage biopharmaceutical company, since 2024. He was Director of the U.S. National Institutes of Health from 2002 to 2008, Executive Vice Dean and Dean for Research at the Johns Hopkins School of Medicine, as well as Professor of Radiology and Biomedical Engineering and Chair of the Department of Radiological Sciences from 1996 to 2002.

Dr. Zerhouni was elected to the National Academy of Medicine in 2002 and to the National Academy of Engineering in 2013. He was elected to the governing council of the National Academy of Medicine in 2025. He serves on the Board of the Lasker Foundation, the Foundation for the National Institutes of Health and Research!America. He received the 2017 Scripps Executive of the Year Award for the pharmaceutical industry and the French Legion of Honor in 2008. Since 2009, he has been a Director of Danaher Corporation, a publicly traded a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world.

Prem A. Lachman, M.D.

Director

Dr. Lachman has been a Director of OPKO since March 2021. He is a healthcare investment manager with more than 35 years of experience in portfolio management, biopharmaceutical investment research and healthcare investment banking. Dr. Lachman founded Maximus Capital in 2001 and currently serves as its general partner. Dr. Lachman previously served as general partner of The Galleon Group from 1998 to 2001 and as Managing Director, Investment Research at Goldman Sachs & Co from 1989 to 1998. Dr. Lachman is a Directors Council board member of the New York Museum of Modern Art, a board member of the New York Metropolitan Opera and a board member of the Department of Surgery at Mount Sinai Medical Center in New York.

Alice Lin-Tsing Yu, M.D., Ph.D.

Director

Dr. Yu has been a Director of OPKO since April 2009. She has been a Professor of Pediatrics for the University of California in San Diego since 1994. From 2003 to 2013, she served as Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Since 2013, she has been a Distinguished Chair Professor at Chang Gung Memorial Hospital at Linkou, and Chang Gung University in Taiwan.

Dr. Yu has also served as a Professor of Pediatrics for the University of California San Diego, where she was the Chief of Pediatric Hematology Oncology. She is an Academician of Academia Sinica, Taiwan. Dr. Yu has also served in several government-appointed positions and is a member of numerous scientific committees and associations.  She has been a long-time member of the Children’s Oncology Group in the United States, serving on the Steering Committee of Neuroblastoma. Dr. Yu currently serves as a director of two private entities, Apexcella Biomedical Inc. and UCT Bioscience, Inc. She was honored with the Pediatric Oncology Award by the American Society of Clinical Oncology (ASCO) in 2020 and the Lifetime Achievement Award from Advances in Neuroblastoma Research Association in 2025.

Roger J. Medel, M.D.

Director

Dr. Medel has been a Director of OPKO since December 2020. He is the co-founder of MEDNAX, a national health solutions partner comprised of the nation’s leading providers of physician services, where he has served as a Director, President and Chief Executive Officer. Dr. Medel currently serves as Chairman of the Board of Istios Health Inc., a privately held healthcare technology company focused on infectious disease care, and Chief Executive Officer of RVM Enterprises, Inc., a privately held investment firm specializing in healthcare and technology growth companies. Dr. Medel has served as a member of the Board of Trustees of the Dana Farber Cancer Institute since 2011 and also has served on the Board of Directors of Schweiger Dermatology Group, a privately held, private equity backed, multi-state dermatology practice, since 2014. He currently serves on the Advisory Committee of MBF Healthcare Partners and, from June 2006 to April 2009, served on the Board of Directors of MBF Healthcare Acquisition Corp.  He previously and was a member of the Board of Trustees of the University of Miami from 2004 to 2012. Dr. Medel actively participates as a member of several medical and professional organizations and previously served on the Board of Directors of InnovaCare Health, a privately held, private equity backed, healthcare company.

Gary J. Nabel, M.D., Ph.D.

Chief Innovation Officer and Director

Dr. Nabel is President and CEO of ModeX Therapeutics, and has served as Chief Innovation Officer and a Director of OPKO since May 2022. He previously worked as Chief Scientific Officer and Senior Vice President of Sanofi until his retirement in 2020e Dr. Nabel graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard, completing his Ph.D. in 1980 and his M.D. two years later, followed by a post-doctoral fellowship with David Baltimore at the Whitehead Institute.

In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, Dr. Nabel was elected to the National Academy of Medicine in 1998 and is a fellow of the American Association of Physicians, and the American Academy of Arts Sciences. Dr. Nabel received the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, the Health and Human Services Secretary’s Award for Distinguished Service. He currently serves on the board of Siga Technologies, a publicly traded a commercial stage pharmaceutical company focused on providing solutions for unmet needs in health security, and Candel Therapeutics, Inc. (NASDAQ: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer.

John A. Paganelli

Director

Mr. Paganelli has served as a Director of OPKO since December 2003. Previously, he served as OPKO's interim CEO and Secretary from 2005 through March 2007, Interim Chief Financial Officer from June 29, 2005 through July 1, 2005, and Chairman of OPKO's Board of Directors from December 2003 until March 2007. Mr. Paganelli also served as President and CEO of Transamerica Life Insurance Company of New York from 1992 to 1997.

Mr. Paganelli is the founder and had been a partner in RFG Associates, a financial planning organization from 197 through 2021. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, an investment company, and served as Chairman of the Board of Pharos Systems International, a software company. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization from 1987 to 2000. Mr. Paganelli was also an officer and director-stockholder of Mike Barnard Chevrolet, an automobile dealership. Mr. Paganelli serves as a Director of Western New York Energy, and previously served on the Board of Trustees of Paul Smith's College from 2001 to 2019.

Richard C. Pfenniger, Jr.

Director

Mr. Pfenniger has served as a Director of OPKO since January 2008. Mr. Pfenniger previously served as CEO and President for Continucare Corporation, a provider of primary care physician and practice management services, from 2003 to 2011 and as Chairman of the Board of Directors of Continucare Corporation from 2002 to 2011. Mr. Pfenniger has also served as CEO and Vice Chairman of Whitman Education Group from 1997 to 2003.

Prior to joining Whitman, he served as Chief Operating Officer of IVAX from 1994 to 1997 and as Senior Vice President-Legal Affairs and General Counsel of IVAX from 1989 to 1994. Prior thereto he was engaged in the private practice of law. Mr. Pfenniger currently serves as a Director of Cocrystal Pharmaceuticals, Inc., a clinical stage biotechnology company, Fluent, Inc., a company utilizing proprietary data science to assist global brands in customer acquisition, and GeneDx Holding Corp., a genomics testing company. Mr. Pfenniger previously served as a director of GP Strategies Corporation, a corporate education and training company, Asensus Surgical, Inc., a medical device company, and BioCardia, a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases. He also serves as Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science.

Steve Rubin

Executive Vice President, Administration and Director

Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a Director since February 2007. 

Mr. Rubin currently serves as a Director of Entera Bio Ltd, a clinical stage company focused on developing oral peptide and protein replacement therapeutics; Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation; Non-Invasive Monitoring Systems, a public shell company; Cocrystal Pharma, a biotechnology company developing new treatments for viral diseases; and Niagen Bioscience, Inc., a global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research; and Red Violet, a leading analytics and information solutions provider. Mr. Rubin previously served as a director of Neovasc, Inc., a company that developed and marketed medical specialty vascular devices

Mr. Rubin previously served as a Director of Castle Brands, Dreams, SafeStitch Medical, Cogent, PROLOR Biotech, BioCardia and VBI Vaccines. 

Subbarao V. Uppaluri, Ph.D.

Director

Dr. Uppaluri has served as a Director of OPKO since March 2026. Previously, Dr. Uppaluri served as Senior Vice President and Chief Financial Officer of the Company from May 2007 until his retirement in July 2012, and as a consultant of the Company until February 2014. He served as Vice President, Strategic Planning and Treasurer of IVAX from 1997 to 2006.  Dr. Uppaluri was Senior Vice President, Senior Financial Officer and Chief Investment Officer with Intercontinental Bank, a publicly traded commercial bank in Florida from 1987 to 1996. In addition, he served in various positions, including Senior Vice President, Chief Investment Officer and Controller, at Peninsula Federal Savings & Loan Association, a publicly traded Florida savings and loan institution, from 1983 to 1987. His prior employment, from 1974 to 1983, included engineering, marketing and research positions with multinational companies and research institutes in India and the United States. Dr. Uppaluri previously served on the boards of Non-Invasive Monitoring Systems, Inc. from 2008 until 2025. Winston Pharmaceuticals Inc., Ideation Acquisition Corp., Tiger X Medical, Inc. and Kidville, Inc.. Dr. Uppaluri currently serves on the board of Baptist Health Homestead Hospital.